Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL2007281 | 0.92 | TSHR (0.36) | PLA2G1BPLA2G2ATSHRLMNA | |
| Alcohol SCHEMBL2126840 | 0.92 | TSHR (0.42) | PLA2G1BPLA2G2ATSHRLMNA | |
| Acetic Acid SCHEMBL1244963 | 0.85 | CHRM1 (0.41) | PLA2G1BPLA2G2ATSHR | |
| SCHEMBL907968 | 0.83 | TSHR (0.44) | TSHRLMNA | |
| SCHEMBL29399686 | 0.83 | — | — | |
| SCHEMBL4635 | 0.83 | — | — | |
| SCHEMBL2487739 | 0.83 | — | — | |
| Butyric Acid SCHEMBL2140387 | 0.80 | HDAC1 (0.52) | TSHRCYP1A2 | |
| Hydrogen Sulfide SCHEMBL5675257 | 0.79 | — | — | |
| Water SCHEMBL3346079 | 0.79 | TSHR (0.42) | TSHRCYP1A2MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459572-B1 | SPIROCYCLIC AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2018-09-12 | — | — | EP | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2459572-A2 | SPIROCYCLIC AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2012-06-06 | — | — | EP | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018037-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | PLA2G1B 4239/4885PLA2G2A 4022/4885TSHR 1318/4885 |
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | PLA2G1B 3955/4885PLA2G2A 4630/4885TSHR 1880/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | PLA2G1B 4239/4885PLA2G2A 4022/4885TSHR 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.